Transplantation

Lisofylline Trial of Among Cancer Patients Undergoing BMT Reported

Published in Cancer Weekly, April 6th, 1998

Cell Therapeutics Inc., Seattle, Washington, announced preliminary results of its first Phase III clinical trial assessing the safety and efficacy of lisofylline in patients with hematological malignancies undergoing bone-marrow transplantation (BMT) from HLA-identical sibling donors.

In this trial, the primary endpoints of reduction in neutropenia-related infections and reduction in BMT-treatment-associated mortality were not met.

Carolyn M. Paradise, M.D., Cell Therapeutics, said the company believes that the results were affected by unusually aggressive treatment regimens clinicians were using with older patients (i.e., >50 years) who were...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1998-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry